Probucol: A new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia

Antone F. Salel, Robert Zelis, H. S. Sodhi, James Price, Dean T. Mason

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Type II hyperlipoproteinemia or hyperbetalipoproteinemia (B-HLP), a condition with considerable atherogenic potential, is one of the most difficult lipid disorders requiring treatment. Since this abnormality responds minimally to dietary therapy alone, supplemental drug therapy is usually essential. Although the available bile-sequestering resins are effective in B-HLP, these substances are unpalatable and constipating. Since lifelong drug therapy is necessary as an adjunct to diet in the treatment of B-HLP, the ideal drug should be both effective and well tolerated. Probucol, a new cholesterol-lowering drug in tablet form without serious adverse effects, was evaluated in a 12-wk double-blind crossover trial in 11 patients with B-HLP whose serum cholesterol levels were in excess of 275 mg/dl. Probucol, in a dosage of 500 mg twice daily, produced a 10% or greater reduction in serum cholesterol levels in all 11 patients. Serum cholesterol was lowered (p G 0.0l) from 353 to 291 mg/dl in the entire group receiving probucol. There was no significant change (p > 0.1) in serum cholesterol (352 ingldl) during placebo administration. There were no untoward drug effects during the study, and all patients maintained excellent compliance to the schedule of medication. results indicate that probucol possesses considerable cholesterol-lowering activity and may be a promising new nontoxic therapeutic agent in type II hyperlipoproteinemia.

Original languageEnglish (US)
Pages (from-to)690-694
Number of pages5
JournalClinical pharmacology and therapeutics
Volume20
Issue number6
DOIs
StatePublished - Jan 1 1976

Fingerprint

Probucol
Hyperlipoproteinemia Type II
Cholesterol
Pharmaceutical Preparations
Serum
Drug Therapy
Therapeutics
Bile
Cross-Over Studies
Tablets
Appointments and Schedules
Placebos
Diet
Lipids

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Salel, Antone F. ; Zelis, Robert ; Sodhi, H. S. ; Price, James ; Mason, Dean T. / Probucol : A new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia. In: Clinical pharmacology and therapeutics. 1976 ; Vol. 20, No. 6. pp. 690-694.
@article{e393f4ce32d64d128effad2b32314226,
title = "Probucol: A new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia",
abstract = "Type II hyperlipoproteinemia or hyperbetalipoproteinemia (B-HLP), a condition with considerable atherogenic potential, is one of the most difficult lipid disorders requiring treatment. Since this abnormality responds minimally to dietary therapy alone, supplemental drug therapy is usually essential. Although the available bile-sequestering resins are effective in B-HLP, these substances are unpalatable and constipating. Since lifelong drug therapy is necessary as an adjunct to diet in the treatment of B-HLP, the ideal drug should be both effective and well tolerated. Probucol, a new cholesterol-lowering drug in tablet form without serious adverse effects, was evaluated in a 12-wk double-blind crossover trial in 11 patients with B-HLP whose serum cholesterol levels were in excess of 275 mg/dl. Probucol, in a dosage of 500 mg twice daily, produced a 10{\%} or greater reduction in serum cholesterol levels in all 11 patients. Serum cholesterol was lowered (p G 0.0l) from 353 to 291 mg/dl in the entire group receiving probucol. There was no significant change (p > 0.1) in serum cholesterol (352 ingldl) during placebo administration. There were no untoward drug effects during the study, and all patients maintained excellent compliance to the schedule of medication. results indicate that probucol possesses considerable cholesterol-lowering activity and may be a promising new nontoxic therapeutic agent in type II hyperlipoproteinemia.",
author = "Salel, {Antone F.} and Robert Zelis and Sodhi, {H. S.} and James Price and Mason, {Dean T.}",
year = "1976",
month = "1",
day = "1",
doi = "10.1002/cpt1976206690",
language = "English (US)",
volume = "20",
pages = "690--694",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

Probucol : A new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia. / Salel, Antone F.; Zelis, Robert; Sodhi, H. S.; Price, James; Mason, Dean T.

In: Clinical pharmacology and therapeutics, Vol. 20, No. 6, 01.01.1976, p. 690-694.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Probucol

T2 - A new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia

AU - Salel, Antone F.

AU - Zelis, Robert

AU - Sodhi, H. S.

AU - Price, James

AU - Mason, Dean T.

PY - 1976/1/1

Y1 - 1976/1/1

N2 - Type II hyperlipoproteinemia or hyperbetalipoproteinemia (B-HLP), a condition with considerable atherogenic potential, is one of the most difficult lipid disorders requiring treatment. Since this abnormality responds minimally to dietary therapy alone, supplemental drug therapy is usually essential. Although the available bile-sequestering resins are effective in B-HLP, these substances are unpalatable and constipating. Since lifelong drug therapy is necessary as an adjunct to diet in the treatment of B-HLP, the ideal drug should be both effective and well tolerated. Probucol, a new cholesterol-lowering drug in tablet form without serious adverse effects, was evaluated in a 12-wk double-blind crossover trial in 11 patients with B-HLP whose serum cholesterol levels were in excess of 275 mg/dl. Probucol, in a dosage of 500 mg twice daily, produced a 10% or greater reduction in serum cholesterol levels in all 11 patients. Serum cholesterol was lowered (p G 0.0l) from 353 to 291 mg/dl in the entire group receiving probucol. There was no significant change (p > 0.1) in serum cholesterol (352 ingldl) during placebo administration. There were no untoward drug effects during the study, and all patients maintained excellent compliance to the schedule of medication. results indicate that probucol possesses considerable cholesterol-lowering activity and may be a promising new nontoxic therapeutic agent in type II hyperlipoproteinemia.

AB - Type II hyperlipoproteinemia or hyperbetalipoproteinemia (B-HLP), a condition with considerable atherogenic potential, is one of the most difficult lipid disorders requiring treatment. Since this abnormality responds minimally to dietary therapy alone, supplemental drug therapy is usually essential. Although the available bile-sequestering resins are effective in B-HLP, these substances are unpalatable and constipating. Since lifelong drug therapy is necessary as an adjunct to diet in the treatment of B-HLP, the ideal drug should be both effective and well tolerated. Probucol, a new cholesterol-lowering drug in tablet form without serious adverse effects, was evaluated in a 12-wk double-blind crossover trial in 11 patients with B-HLP whose serum cholesterol levels were in excess of 275 mg/dl. Probucol, in a dosage of 500 mg twice daily, produced a 10% or greater reduction in serum cholesterol levels in all 11 patients. Serum cholesterol was lowered (p G 0.0l) from 353 to 291 mg/dl in the entire group receiving probucol. There was no significant change (p > 0.1) in serum cholesterol (352 ingldl) during placebo administration. There were no untoward drug effects during the study, and all patients maintained excellent compliance to the schedule of medication. results indicate that probucol possesses considerable cholesterol-lowering activity and may be a promising new nontoxic therapeutic agent in type II hyperlipoproteinemia.

UR - http://www.scopus.com/inward/record.url?scp=0017038379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017038379&partnerID=8YFLogxK

U2 - 10.1002/cpt1976206690

DO - 10.1002/cpt1976206690

M3 - Article

C2 - 186224

AN - SCOPUS:0017038379

VL - 20

SP - 690

EP - 694

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -